Prostate
Cancer
Red
color connotes government-sponsored trials.
Green color connotes pharmaceutical-sponsored
trials.
C9594
– Patients with metastatic prostate cancer are randomly allocated
to:
Continuous
therapy with Zoladex plus Casodex
or
Intermittent therapy with Zoladex plus Casodex
C99904
– Prostate cancer patients recently treated with radical prostatectomy
who are considered at high risk of recurrence are randomly allocated
to receive:
Zoladex
+ Casodex for 2 years
or
Zoladex + Casodex plus 6 cycles of chemotherapy with Mitoxantrone
and Prednisone
C90202
– Patients with prostate cancer and bone metastasis that have
recently started hormonal therapy or have not begun this therapy
are eligible. Patients are randomly allocated to receive :
Zometa
(potent bone building medicine)
or
Placebo –these patients will all be offered Zometa at the
time that the cancer progresses
C90401 – Men with advanced prostate cancer who have not received chemotherapy are eligible for this trial. Patients are randomly assigned to chemotherapy (Docetaxel + prednisone) with or without bevacizumab(Avastin), a protein that interferes with blood vessel growth.
C70004
– Men with biopsy of prostate that demonstrates precancerous
condition (PIN) are eligible. Patients are randomly allocated to
receive:
High
dose selenium
or
Placebo
Red
color connotes government-sponsored trials.
Green color connotes pharmaceutical-sponsored
trials.
|
